WSJ Attack on Sham Surgery Is About Healthy Profits, Not Patients

Feb 20 2014, 7:09pm CST | by

In an op-ed piece in the  Wall Street Journal Scott Gottlieb, a former FDA official under George W. Bush, argues that the FDA should stop requiring medical device companies to use sham procedures when they test certain new products. To support his argument he uses the example of renal denervation, a once highly promising new technology for lowering blood pressure. Unfortunately, Gottlieb extracts exactly the wrong lesson from this story, because the renal denervation story is a perfect example of why sham procedures can be both necessary and more ethical than any alternative.

At first glance it’s hard to disagree with Gottlieb. The idea that patients would receive an invasive surgical procedure that could do no good appears abhorrent. “Research that introduces harm or risk with no opportunity for benefit would seem to conflict with the principles governing research on humans,” writes Gottlieb.

But the same exact words could and should be used to describe medical devices with no proven benefit. In such cases, however, instead of the relatively small number of patients potentially exposed to harm in clinical studies, the number of patients exposed to harm in the real world may be larger by many orders of magnitude.

Let’s examine this issue using the same example used by Gottlieb: renal denervation. In case you haven’t been following this story, for the last few years renal denervation– the zapping of the renal artery with electric energy to lower blood pressure– has been widely considered to be one of the most exciting and promising new medical technologies around. Based on preliminary– and uncontrolled– studies renal denervation was thought to consistently lower blood pressure by an astounding 25-30 mm Hg and was hailed by many hypertension experts as a potential breakthrough cure for people who had persistently and dangerously high blood pressure even after taking several blood pressure pills.

Then reality intruded. Medtronic announced last month that its pivotal trial of renal denervation had not met its primary endpoint. It became clear that renal denervation was neither a cure nor a breakthrough. Although the details of the trial have not been revealed, the underlying cause of the trial’s failure is fairly well understood. Last summer a few skeptical British researchers carefully examined the underlying science and concluded– contrary to what industry and the experts had been saying– that the true blood pressure lowering effect of renal denervation wold be much smaller than predicted. And the reason was simple: because all the early studies had been either uncontrolled or poorly controlled, the companies and the researchers had greatly overestimated the true effect of renal denervation. The Medtronic trial, by contrast, was much more rigorous, in part because it included the notorious sham procedures decried by Gottlieb.

As Gottlieb notes, renal denervation “is already available in Europe, where regulators approved it based on traditional studies.” Gottlieb fails to notice how this undercuts his point. After all, many thousands of people in Europe have received a device from which they may have received no or little benefit and may have experienced harm. But this doesn’t seem to concern Gottlieb. Here, writing about the effect of well-controlled trials, is what does concern Gottlieb:

All of this raises development costs—and it encourages firms to skip the U.S. market and commercialize new products overseas. This can suppress innovation. When a sham trial doesn’t produce positive results, the company may have exhausted its resources and have no capital left to refine a good idea into a beneficial product.

But, as the renal denervation story demonstrates, the trial didn’t “suppress innovation.” Instead it showed that the so-called “innovation” was, well, a sham.

Although he waves the flag for ethics, it’s clear that what really motivates Gottlieb to stand up and salute is business profits. He’s far more interested in the health of businesses than he is in the health of patients. If he were actually interested in the welfare of patients he would pay attention to the medical details of his examples. But instead his real concern seems to be the health of the bottom line.

This isn’t the first time Gottlieb has confused ethics and economics. In 2012 he wrote about another new medical technology, transcatheter aortic valve replacement (TAVR), and argued that the FDA and CMS had prevented the American public from benefiting from the procedure. As I wrote then, Gottlieb completely ignored the complex issues of the story, spinning an untrue but compelling tale in which the forces of government were preventing desperately sick people from getting a new life-saving therapy.

It seems clear that Gottlieb has very little interest in a serious discussion of clinical trials or the best way to test and introduce new medical technology. What he really wants is to provide a basis for campaign slogans that undermine the FDA and government involvement in medicine. It doesn’t matter that sham surgery is a complex issue or that TAVR had as much potential danger as benefit. It’s easy to score polemical points by scaring people, telling them that they will be subject to harmful procedures or that their government is preventing them from getting life-saving treatments. It’s much harder, and less politically advantageous, to consider the full complexity of these issues.

Update:

Sanjay Kaul sent the following comment:

“Those who cannot remember the past are condemned to repeat it”.

There are many examples where the “scam” of some device-based therapies has been exposed by the “sham” procedure. How can anyone forget the classic examples of laser TMR (TransMyocardial Revascularization) or Pacemaker for hypertrophic cardiomyopathy, both touted as breakthrough interventions. It would not surprise me one bit if RF ablation for atrial fibrillation ends up with a similar fate!

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Chinese unmanned lunar orbiter returns home
Beijing, Nov 1 (IANS) China succeeded Saturday in the world's first mission to the Moon and back, becoming the third nation to do so after the former Soviet Union and the US.
 
 
China pledges $81 mn financial assistance for Afghanistan
Beijing, Oct 31 (IANS) China Friday pledged to provide non-reimbursable assistance of 500 million yuan (about 81 million dollars) to Afghanistan this year at an international meeting on Afghanistan held here.
 
 
EU seeks talks with Russia over goods duties: WTO
Geneva, Oct 31 (IANS) The European Union (EU) has sought a consultation with Russia over the tariffs the latter imposed on certain agricultural and manufactured goods, the World Trade Organisation (WTO) said Friday.
 
 
Virgin Galactic's spaceship crashes during test flight
Los Angeles, Nov 1 (IANS) A passenger rocket plane developed by Virgin Galactic's crashed Friday after suffering an "in-flight anomaly" during a powered test flight over the US state of California, the company said.
 
 
 

Latest from the Network

'Interstellar' about bonds of love: Jessica Chastain
Los Angeles, Nov 1 (IANS) Actress Jessica Chastain says that her forthcoming science fiction "Interstellar" is also about fathers and the bonds of love. In the movie, she plays Matthew McConaughey's character's...
Read more on Celebrity Balla
 
Chinese unmanned lunar orbiter returns home
Beijing, Nov 1 (IANS) China succeeded Saturday in the world's first mission to the Moon and back, becoming the third nation to do so after the former Soviet Union and the US. The test lunar orbiter, nicknamed "Xiaofei...
Read more on Business Balla
 
Avril Lavigne feels 'a bit lost'
Avril Lavigne feels ''a bit lost'' amid rumors her marriage to Chad Kroeger is on the rocks. The 'Here's to Never Growing Up' singer, who recently celebrated her 30th birthday without her husband, reportedly thinks her...
Read more on Celebrity Balla
 
Scott Disick is battling severe anxiety
Scott Disick admits his anxiety makes him ''literally want to jump out of my skin.'' The 31-year-old reality TV star - whose longtime girlfriend Kourtney Kardashian is set to give birth to their third child in December...
Read more on Celebrity Balla
 
Demi Lovato wants to be 'sexier' this Halloween
Demi Lovato says working out has boosted her confidence. The 22-year-old singer, who sought treatment for a number of issues, including an eating disorder, in rehab in late 2010, is planning to wear a ''sexier''...
Read more on Celebrity Balla
 
Usher's son is his toughest critic
Usher's son doesn't think he's a great singer. The 'She Came To Give It To You' hitmaker admits his youngest child, Nayvid, five, is very critical of his performances. The 36-year-old star said: ''He doesn't care about...
Read more on Celebrity Balla
 
Rogen may star in Steve Jobs biopic
Los Angeles, Nov 1 (IANS) Actor Seth Rogen is reportedly in talks with Sony studio to star as Apple co-founder Steve Wozniak in their upcoming Steve Jobs biopic. "Zero Dark Thirty" star Jessica Chastain is also being...
Read more on Celebrity Balla
 
Lindsay Lohan denies dating Tom Cruise
London, Nov 1 (IANS) Actress Lindsay Lohan has denied she's secretly dating actor Tom Cruise. The duo reportedly swapped numbers here recently, and have been meeting up since. But now Lohan's representative said the...
Read more on Celebrity Balla
 
Three Iraqis arrested on terror charges in Switzerland
Geneva, Nov 1 (IANS) Swiss authorities Friday said they arrested three Iraqi nationals suspected of planning a terrorist attack in Europe. The office of the attorney general of Switzerland said in a statement that the...
Read more on Politics Balla
 
Pakistan repatriates 29 Afghans
Islamabad, Oct 31 (IANS) Pakistan handed over 29 Afghans arrested during a military operation in its northwestern tribal region to Afghan authorities, the army said Friday. The Pakistani security forces had launched a...
Read more on Politics Balla